A detailed history of Axxcess Wealth Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Axxcess Wealth Management, LLC holds 2,850 shares of VRTX stock, worth $1.29 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
2,850
Previous 2,445 16.56%
Holding current value
$1.29 Million
Previous $1.15 Million 15.62%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$460.0 - $505.78 $186,300 - $204,840
405 Added 16.56%
2,850 $1.33 Million
Q2 2024

Aug 09, 2024

BUY
$392.81 - $485.53 $85,239 - $105,360
217 Added 9.74%
2,445 $1.15 Million
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $228,306 - $249,804
560 Added 33.57%
2,228 $931,000
Q4 2023

Feb 06, 2024

SELL
$343.0 - $410.68 $112,847 - $135,113
-329 Reduced 16.47%
1,668 $678,000
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $231,653 - $248,285
685 Added 52.21%
1,997 $694,000
Q2 2023

Aug 08, 2023

BUY
$314.42 - $351.91 $18,865 - $21,114
60 Added 4.79%
1,312 $461,000
Q1 2023

May 03, 2023

SELL
$283.23 - $323.1 $195,711 - $223,262
-691 Reduced 35.56%
1,252 $394,000
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $258,041 - $290,296
-903 Reduced 31.73%
1,943 $561,000
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $71,743 - $80,048
-262 Reduced 8.43%
2,846 $824,000
Q2 2022

Aug 11, 2022

BUY
$234.96 - $292.55 $5,169 - $6,436
22 Added 0.71%
3,108 $876,000
Q1 2022

Aug 11, 2022

BUY
$221.42 - $260.97 $83,696 - $98,646
378 Added 13.96%
3,086 $805,000
Q4 2021

Aug 11, 2022

BUY
$177.01 - $223.45 $479,343 - $605,102
2,708 New
2,708 $595,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Axxcess Wealth Management, LLC Portfolio

Follow Axxcess Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axxcess Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Axxcess Wealth Management, LLC with notifications on news.